Ovarian Stimulation After Dehydroepiandrosterone Supplementation in Poor Ovarian Reserve
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
• There was no significant difference between the two groups’ demographic data. • There was no significant difference between the two groups’ baseline investigations and that indicated good randomization of cases and control. • The study group showed a statistically significant difference between the baseline investigations before taking DHEA supplementation and after 2 months of taking the DHEA supplementation, the mean basal FSH decreased from 12.16±0.94 to 10.19±1.22 and that was statistically significant. The mean AMH level increased from 0.81±0.14 to 0.99±0.17 but it failed to reach significance level. The basal E2 level decreased from 32.20±5.50 to 21.48±5.84 and that was statistically significant. The mean Antral follicular count by U/S increased from 1.68±0.63 to 2.72±0.89 and that was statistically significant. • The comparison between the study group baseline investigations after 2 months of DHEA supplementation and the control group showed that the mean basal FSH of the study group was 10.19±1.22 compared with 11.94±1.11 in the control group, and that was statistically significant. The mean AMH level in the study group was 0.99±0.17 compared to 0.844±0.141 in the control group showed an improvement in the study group but it failed to reach significance level. The basal E2 level in the study group was 21.48±5.84 compared with 32.92±6.49 in the control group and that was statistically significant. The mean Antral follicular count by U/S in the study group was 2.72±0.89 compared to 1.88±0.73 in the control group and that was statistically significant.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- Female
入选标准
- •1.Serum AMH <1.1 ng/ml
- •2.Serum FSH =10 mIU/L and =15 mIU/L on day 3 of cycle
- •3.Low antral follicle counts (AFC) = 4 on Day 3 of cycle
排除标准
- •1.Patients exposed to cytotoxic or radiotherapy for pelvic malignancies.
- •2.Patients on herbal or hormonal therapy.
- •3.Patients with cystectomy or oophorectomy.
- •4.Cases contraindicated to be supplemented with DHEA
- •oChronic kidney diseases,
- •oChronic liver diseases,
- •oBreast or Uterine cancers,
- •oEndometriosis,
- •oAdrenal gland hyperplasia,
- •oPsychological disorders like depression.
- •5.Hyperprolactinaemia.
- •6.Polycystic ovaries syndrome.
- •7.Severe male factor.